Early-Life *Pseudomonas aeruginosa* Infection in Cystic Fibrosis and Lung Disease Progression

Argyri Petrocheilou, MD¹, Maria Papagrigoriou-Theodoridou, MD², Athanasios Michos, MD², Stavros-Eleftherios Doudounakis, MD¹*, Ioanna Loukou, MD¹, and Athanasios Kaditis, MD³

Abstract

Lung disease in cystic fibrosis (CF) starts early, with studies identifying abnormalities on chest computed tomography (CT) scan even in infancy.¹² Patients develop initially transient *Pseudomonas aeruginosa* infections that can be eradicated, but later in life *P aeruginosa* usually persists and chronic infection develops.³ Chronic infection is associated with worse lung function, nutritional status, and abnormal radiographic scores.⁴⁻⁶ These adverse outcomes were reported prior to the era of aggressive eradication treatment of *P aeruginosa* infections.⁵⁻⁷ Cohort studies that included patients after the introduction of eradication strategies, such as the study by Amin et al and the EPIC study, demonstrated that *P aeruginosa* infection was not associated with greater decline in lung function and it did not affect annual change of weight and height. However, in these reports the mean age of initial *P aeruginosa* acquisition ranged between 6.5 and 7.1 years.⁸⁻⁹

Thus, the aim of the present cohort study was to investigate whether infection with *P aeruginosa* during the first year of life was associated with worse findings

Background

An increasing body of evidence indicates that cystic fibrosis (CF) lung disease starts very early in life with studies identifying abnormalities on chest computed tomography (CT) scan even in infancy.¹² Patients develop initially transient *Pseudomonas aeruginosa* infections that can be eradicated, but later in life *P aeruginosa* usually persists and chronic infection develops.³ Chronic infection is associated with worse lung function, nutritional status, and abnormal radiographic scores.⁴⁻⁶

These adverse outcomes were reported prior to the era of aggressive eradication treatment of *P aeruginosa* infections.⁵⁻⁷ Cohort studies that included patients after the introduction of eradication strategies, such as the study by Amin et al and the EPIC study, demonstrated that *P aeruginosa* infection was not associated with greater decline in lung function and it did not affect annual change of weight and height. However, in these reports the mean age of initial *P aeruginosa* acquisition ranged between 6.5 and 7.1 years.⁸⁻⁹

Thus, the aim of the present cohort study was to investigate whether infection with *P aeruginosa* during the first year of life was associated with worse findings

Keywords
cystic fibrosis, lung function, chest CT scan, BMI, *Pseudomonas aeruginosa*, infection

Received August 21, 2017. Accepted for publication September 18, 2017.
on chest CT, and lower lung function and body mass index (BMI) at the age of 6 to 7 years. The effect of other pathogens, such as Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, and Aspergillus species, which play a role in disease progression, was also taken into consideration.10

Materials and Methods

Data Collection

The study was conducted at the Aghia Sophia Children’s Hospital Cystic Fibrosis Center and was approved by the hospital’s institutional review board. Data of children with CF who (a) were 6 to 10 years old at the time of the study, (b) were diagnosed with CF in the first year of life, and (c) had a routine chest CT scan at the age of 6 to 7 years were analyzed. Patients who were diagnosed after the first year of life were excluded.

Data were collected by review of clinic charts. Parameters that were recorded included cystic fibrosis transmembrane conductance regulator (CFTR) genotype, respiratory culture results and antibiotic courses during the first 6 years of life, and chest CT findings at age 6 to 7 along with the closest BMI and forced expiratory volume percent predicted (FEV1%) predicted measurements. All CT scans were interpreted by a pediatric radiologist, according to standard hospital protocol, and findings consistent with bronchiectasis, bronchial wall thickening, and infiltrates/atelectasis were noted.

CFTR Mutations, Respiratory Cultures, Growth Parameters, and Spirometry

Categorization of CFTR mutations was based on CFTR mutation class, as follows: “minimal CFTR function” when both mutations belonged to classes I to III and “residual CFTR function” when at least one mutation belonged to classes IV to VI.11-13 Respiratory specimens were obtained at every visit, at least every 3 months, by cough swab or sputum expectoration and were cultured at the clinical microbiology laboratory according to standard operational procedures.14,15 All patients with P aeruginosa were treated with oral ciprofloxacin, inhaled antipseudomonal antibiotics, and/or intravenous antipseudomonal antibiotics.

Standing height was measured by a stadiometer and body weight by a calibrated scale. BMI was calculated and converted to z scores using the World Health Organization AnthroPlus online calculator. Spirometry was completed according to the American Thoracic Society and European Respiratory Society guidelines. Calculation of FEV1% predicted values was carried out using the prediction equations by Wang et al for male children aged 6 to 17 years and female children aged 6 to 15 years.16 For male patients aged ≥18 years and female subjects ≥16 years the reference values published by Hankinson et al were applied.17

Primary Outcome Measures and Data Analysis

Presence of abnormal chest CT findings at age 6 to 7 years was the primary outcome measure and BMI and FEV1% predicted at the same age were secondary outcomes. The time of P aeruginosa acquisition (at least one positive culture in the first year of life vs at the age of 2-6 years). Confounding factors that were considered in the statistical analysis were gender, CFTR mutation class, and acquisition (at least one positive culture) of other pathogens, that is, S aureus, H influenzae, Stenotrophomonas maltophilia, and Achromobacter xylooxidans.

The associations between the explanatory variable and the outcome measures were explored using logistic regression analysis (chest CT findings) or linear regression (BMI z score and FEV1% predicted). Results are presented as odds ratios (ORs) and 95% confidence intervals (CIs) or standardized coefficients. Statistical analysis was completed using SPSS 20 (SPSS Inc, Chicago, IL).

Results

Patients’ Characteristics

A total of 45 children with CF were between 6 and 10 years old when the study was conducted, were diagnosed before 1 year of age, and had a routine chest CT scan at the age of 6 to 7 years. Of those children, 65.6% were female, 84.4% carried mutations with minimal function, and 86.66% were pancreatic insufficient. Most patients were diagnosed based on clinical symptoms as newborn screening is not universally performed yet in Greece. Of the 45 children, 12 (26.7%) presented with meconium ileus, 10 (22.2%) with dehydration, 12 (26.7%) with gastrointestinal symptoms or failure to thrive, 4 (8.9%) with respiratory symptoms, while newborn screening led to the diagnosis in 4 (8.9%).

All 45 children had at least one culture positive for P aeruginosa during the first 6 years of life. Mean (±) BMI z score was 0.47 (±1.25) and mean FEV1% predicted was 98.1% (50.7% to 130.7%). Mean age for the first P aeruginosa acquisition was 19.4 months (3-84). Twenty-five of 45 (55.5%) patients had their first positive culture for P aeruginosa during the first year of life.
Moreover, 31 (68.9%) subjects had at least one positive culture during the first year of life for any of the following microbes: *S. aureus*, *H. influenzae*, *S. maltophilia*, and *A. xylooxidans*.

**Associations Between Pseudomonas aeruginosa Infection in the First Year of Life and Outcome Measures**

The association between *P. aeruginosa* acquisition in infancy and chest CT findings was not significant (OR = 0.30; 95% CI = 0.07-1.35; *P* = .12; Table 1). No significant relationships was demonstrated between age at first *P. aeruginosa* infection and BMI *z* score or FEV1% predicted (*P* = .882 and *P* = .172, respectively; Table 2). CFTR mutation with minimal function was related to increased risk of abnormal chest CT findings and was negatively associated with FEV1% predicted (*P* = .035 and *P* = .04, respectively; Table 2).

**Discussion**

In the present study, CFTR mutation with minimal function but not *P. aeruginosa* infection during the first year of life was significantly associated with abnormal findings on CT scan at age 6 to 7 years. This finding is in line with the conclusion of the Early Pseudomonas Infection Control (EPIC) observational study, which states that in the current era of early treatment of respiratory infection, genetic determinants might be more important in CF lung disease progression than *P. aeruginosa* acquisition.

In the observational arm of the EPIC study, children with CF less than 12 years of age with baseline respiratory cultures negative for *P. aeruginosa* were enrolled and were monitored for a mean of 4.6 years. The mean age of subsequent *P. aeruginosa* acquisition was 6.5 years and no significant difference was identified in the annual change of FEV1% predicted or annual change in weight and height between children who acquired *P. aeruginosa* and those who remained negative.8

Additionally, in a single-center (Toronto), retrospective cohort study of CF patients who were monitored from 1990 to 2007, it was shown that *P. aeruginosa* infection was not associated with decreased lung function. The mean age of *P. aeruginosa* new infection was 7.1 years and all patients were treated.9 Thus, both the EPIC and the Toronto studies involved older patients when compared with those included in the present cohort.

In another large study (AREST CF), isolation of pro-inflammatory pathogens, namely, *P. aeruginosa*, *S. aureus*, *H. influenzae*, *S. pneumoniae*, and *Aspergillus* species from bronchoalveolar lavage fluid during the first 2 years of life was not associated with subsequently reduced lung function after adjustment for other risk factors.10 Nevertheless, there was a relationship of infection due to pro-inflammatory pathogens and neutrophilic inflammation with chest CT findings in infancy.2,18

---

**Table 1.** Association Between Early-Life *Pseudomonas aeruginosa* Infection and Abnormal Chest CT Findings at Age 6 to 7 Years (Primary Outcome Measure; Abnormal Chest CT) in Children With Cystic Fibrosis.

|                     | OR    | 95% CI         | P       |
|---------------------|-------|----------------|---------|
| Gender              | 1.02  | 0.26-4.02      | .98     |
| CFTR functional class I to III | 11.67 | 1.12-115.06    | .04     |
| Other infection at age less than 1 year | 1.00  | 0.17-5.95      | .99     |
| *Pseudomonas aeruginosa* infection at age less than 1 year | 0.30  | 0.07-1.35      | .12     |

Abbreviations: CT, computed tomography; OR, odds ratio; CI, confidence interval; CFTR, cystic fibrosis transmembrane conductance regulator.

**Table 2.** Associations Between Early-Life *Pseudomonas aeruginosa* Infection and FEV1 % Predicted or BMI *z* Score.

|                              | Regression Model 1, FEV1 % Predicted | P       | Regression Model 2, BMI *z* Score | P       |
|------------------------------|--------------------------------------|---------|----------------------------------|---------|
| Gender                       | -0.074                               | .621    | -0.13                            | .933    |
| CFTR functional class “minimal” | 0.315                               | .040    | 0.211                            | .183    |
| Other infection at age less than 1 year | -0.114                              | .479    | -1.037                           | .306    |
| *Pseudomonas aeruginosa* infection at age less than 1 year | 0.222                               | .172    | -0.150                           | .882    |

Abbreviations: FEV1%, forced expiratory volume percent predicted; BMI, body mass index.
The patient sample of the current cohort was representative of our center’s patient population. Diagnosis was based on clinical manifestations, and patients who were diagnosed after the age of 1 year were not included in the present analysis. We speculate that the absence of an association between early *Pseudomonas aeruginosa* and abnormal chest CT findings in later life can be attributed to the aggressive treatment interventions for eradication. The potential effect of other pathogens on outcomes was explored but it was not significant.

Oropharyngeal swabs were used to obtain the majority of respiratory samples because most patients were too young to expectorate sputum. Even though this is the standard of care, controversy exists as to whether oropharyngeal cultures are representative of the lower respiratory tract flora. Bronchoscopy with bronchoalveolar lavage were not performed for identifying markers of inflammation, which may have an impact on the selected outcomes.

### Conclusion

In conclusion, in the current era of aggressive eradication treatments, genetic determinants might be more important than age of first infection for predicting the severity of lung disease, although larger studies are needed to answer this question.

### Author Contributions

AP: Contributed to conception and design; contributed to acquisition, analysis, and interpretation; drafted manuscript; critically revised manuscript; gave final approval; agrees to be accountable for all aspects of work ensuring integrity and accuracy.

MPT: Contributed to conception and design; contributed to interpretation; critically revised manuscript; gave final approval; agrees to be accountable for all aspects of work ensuring integrity and accuracy.

AM: Contributed to design; contributed to interpretation; critically revised manuscript; gave final approval; agrees to be accountable for all aspects of work ensuring integrity and accuracy.

SED: Contributed to conception and design; contributed to interpretation; critically revised manuscript; gave final approval; agrees to be accountable for all aspects of work ensuring integrity and accuracy.

IL: Contributed to conception; contributed to interpretation; critically revised manuscript; gave final approval; agrees to be accountable for all aspects of work ensuring integrity and accuracy.

AK: Contributed to conception and design; contributed to analysis and interpretation; critically revised manuscript; gave final approval; agrees to be accountable for all aspects of work ensuring integrity and accuracy.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### References

1. Thia LP, Calder A, Stocks J, et al; London Cystic Fibrosis Collaboration. Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age? *Thorax*. 2014;69:320-327.

2. Sly PD, Brennan S, Gangell C, et al; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. *Am J Respir Crit Care Med*. 2009;180:146-152.

3. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of *Pseudomonas aeruginosa* in young children with cystic fibrosis. *J Infect Dis*. 2001;183:444-452.

4. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. *Pediatr Pulmonol*. 2001;32:356-366.

5. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatr Pulmonol*. 2002;34:91-100.

6. Konstan MW, Morgan WJ, Butler SM, et al; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. *J Pediatr*. 2007;151:134-139.

7. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after *Pseudomonas aeruginosa* acquisition. *Pediatr Pulmonol*. 2001;32:277-287.

8. Zemanick ET, Emerson J, Thompson V, et al; EPIC Study Group. Clinical outcomes after initial *Pseudomonas aeruginosa* acquisition in cystic fibrosis. *Pediatr Pulmonol*. 2015;50:42-48.

9. Amin R, Lam M, Dupuis A, Ratjen F. The effect of early *Pseudomonas aeruginosa* treatment on lung function in pediatric cystic fibrosis. *Pediatr Pulmonol*. 2011;46:554-558.

10. Ramsey KA, Ranganathan S, Park J, et al; AREST CF. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. *Am J Respir Crit Care Med*. 2014;190:1111-1116.

11. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. *Ann Hum Genet*. 2003;67(pt 5):471-485.
12. Rosenfeld M, Emerson J, McNamara S, et al; EPIC Study Group Participating Clinical Sites. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. *Pediatr Pulmonol*. 2010;45:934-944.

13. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. *Lancet*. 2003;361:1671-1676.

14. The UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group. *Cystic Fibrosis. Our Focus. Laboratory Standards for Processing Microbiological Samples from People with Cystic Fibrosis*. London, England: Cystic Fibrosis Trust; 2010.

15. Gillian P. Respiratory cultures from cystic fibrosis patients. In: Isenberg HD, ed. *Clinical Microbiology Procedures Handbook*. 3rd ed. Washington, DC: ASM Press; 2010:3.11.3.1-3.11.3.9.

16. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. *Pediatr Pulmonol*. 1993;15:75-88.

17. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. *Am J Respir Crit Care Med*. 1999;159:179-187.

18. Mott LS, Park J, Murray CP, et al; AREST CF. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. *Thorax*. 2012;67:509-516.

19. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. *Pediatr Pulmonol*. 1996;21:267-275.

20. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. *Pediatr Pulmonol*. 1999;28:321-328.

21. Jung A, Kleinau I, Schönian G, et al. Sequential genotyping of *Pseudomonas aeruginosa* from upper and lower airways of cystic fibrosis patients. *Eur Respir J*. 2002;20:1457-1463.